Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | CCR8 | P51685 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.36 |
| ▸ | BCR | P11274 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9235358 | 0.80 | CCR1 (0.65) | CYP2A6CCR1CCR5CCR8METAP2 | |
| SCHEMBL28590584 | 0.79 | ASIC3 (0.44) | ASIC3TGFBR1 | |
| SCHEMBL2431863 | 0.79 | CCR1 (0.58) | CYP2A6CCR1CCR5CCR8NOS3 | |
| SCHEMBL27729200 | 0.79 | KIF11 (0.39) | CYP2A6METAP2ASIC3 | |
| SCHEMBL2157068 | 0.78 | CCR1 (0.61) | CYP2A6CCR1CCR5CCR8METAP2 | |
| SCHEMBL97926 | 0.77 | KDM4E (0.37) | CYP2A6CCR1CCR5CCR8METAP2 | |
| SCHEMBL29446990 | 0.77 | CYP2A6 (0.67) | CYP2A6CCR1CCR5CCR8METAP2 | |
| SCHEMBL842170 | 0.77 | CYP2A6 (0.67) | CYP2A6CCR1CCR5CCR8METAP2 | |
| SCHEMBL2437189 | 0.77 | CLK4 (0.44) | TGFBR1GRM5 | |
| SCHEMBL4714992 | 0.76 | KDM4E (0.36) | CCR1CCR8KDM4EMEN1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392032-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | Arena Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023026185-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-19 | — | — | US | claimed |
| EP-3464292-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2017214002-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | claimed |
| EP-4392032-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | Arena Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4384169-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE | Arena Pharmaceuticals, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023026185-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023017388-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE | ARENA PHARMACEUTICALS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-109563103-B | Modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210340154-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-10479797-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190292196-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-19 | — | — | US | disclosed |
| WO-2019163959-A1 | CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCNET ELEMENT, AND ELECTRON-TRANSPORTING MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT | 東ソー株式会社 | 2019-08-29 | — | — | WO | disclosed |
| EP-3464292-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017214002-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479797-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | CYP2A6 527/4885CCR1 1885/4885CCR5 913/4885 |
| US-20190292196-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP2A6 527/4885CCR1 1885/4885CCR5 913/4885 |
| US-20210340154-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP2A6 537/4885CCR1 1864/4885CCR5 904/4885 |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP2A6 527/4885CCR1 1885/4885CCR5 913/4885 |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | CYP2A6 527/4885CCR1 1885/4885CCR5 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.